Career history of Ross G. Clark
Former positions of Ross G. Clark
| Companies | Position | Start | End |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Director/Board Member | 01/12/2001 | 21/06/2008 |
| Chief Tech/Sci/R&D Officer | 01/12/2001 | 21/06/2008 | |
| Auckland University | Corporate Officer/Principal | 01/09/1997 | 21/06/2008 |
| NeuronZ Ltd. | Chief Tech/Sci/R&D Officer | 01/10/1997 | 01/01/2000 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/01/1990 | 01/01/1997 |
| ViaLactia Biosciences (NZ) Ltd. | Director/Board Member | 01/07/1999 | - |
| Tercica Ltd. | Corporate Officer/Principal | 01/09/2000 | - |
Training of Ross G. Clark
| Massey University | Doctorate Degree |
Statistics
International
| New Zealand | 6 |
| United States | 3 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 5 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Tercica Ltd. | |
| NeuronZ Ltd. | |
| ViaLactia Biosciences (NZ) Ltd. | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Ross G. Clark
- Experience
